Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!
Application of Bawei Swertia Composition in Preparation of Drugs for Treating Atrophic Gastritis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of atrophic gastritis and swede, applied in the field of medicine
Active Publication Date: 2020-12-22
SHANDONG JINHE DRUG RES DEV
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] Bawei Zhangyacai Pills are mainly used for the treatment of cholecystitis and jaundice hepatitis. It has been reported in the literature that the drug can also be used for neonatal hyperbilirubinemia. There is no literature or research report on its use in gastritis, especially atrophy Treatment of gastritis
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
experiment example 1
[0015] Experimental Example 1: Animal experiment on treating atrophic gastritis with Bawei Zhangyacai Pill
[0016] 1 Experiment purpose:
[0017] To observe the therapeutic effect of Bawei Zhangyacai Pill on MNNG-induced chronic atrophic gastritis (CAG) in rats.
[0018] 2 drugs and reagents
[0019] 2.1 Experimental animals
[0020] SPF grade Wistar rats, half male and half male, license number: SCXK (Lu) 20110002, provided by Shandong Lukang Pharmaceutical Co., Ltd.
[0021] 2.2 Experimental drugs
[0022] Test drug: Bawei Swertia Pills, specification 0.24g / pill, batch number: 20121024, provided by Jinhe Tibetan Medicine Co., Ltd. The daily dosage for adults is 2.4g, and the standard adult body weight is calculated as 60kg, so the clinical daily dosage for adults is 0.04g / kg. Prepare a 1g / ml suspension with distilled water just before use.
[0023] Positive control drug: Moluodan, Handan Moluodan Pharmaceutical Co., Ltd., batch number: 110417. The daily dosage of Mol...
experiment example 2
[0103] Experimental Example 2: Clinical Observation of Bawei Zhangyacai Pills in Treating Atrophic Gastritis
[0104] 1 Materials and methods
[0105] 1.1 Inclusion and exclusion criteria
[0106] 1.1.1 Inclusion criteria:
[0107] ①Meet the diagnostic criteria for chronic atrophic gastritis;
[0108] ② Chronic atrophic gastritis was diagnosed by gastroscopy and pathological examination within 1 month before inclusion in the trial;
[0109] ③Age between 19-70 years old, regardless of gender. ④Voluntary acceptance of the drug treatment, informed consent.
[0110] 1.1.2 Exclusion criteria:
[0111] ① Those who are under 19 years old or over 70 years old, pregnant or breastfeeding women, allergic constitution and allergic to this drug;
[0112] ② Combined with peptic ulcer, severe dysplasia or suspected malignant transformation;
[0113] ③ Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system.
[0114] 1.2 General information ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention discloses new uses of Baweizhangyacaiwan. According to the present invention, the Baweizhangyacaiwan is clinically used for cholecystitis and early icteric hepatitis; the parmacological and clinical study results show that the Baweizhangyacaiwan can be used for atrophic gastritis, can significantly improve the general symptoms of atrophic gastritis animal models, can significantly increase the gastric free mucus amount (P is less than 0.05), and can significantly improve the histopathological change in the stomach; the biochemical index detection results show that the Baweizhangyacaiwan can provide the treatment effects by reducing the lipid peroxide (MDA) formation and the NO level and increasing the interleukin-12 level; and the clinical study results show that thetotal effective rate of the Baweizhangyacaiwan in the treatment of atrophic gastritis is 87.50%, and the Baweizhangyacaiwan can significantly improve symptoms such as gastrectasia, stomachache, belching, sour regurgitation and poor appetite.
Description
technical field [0001] The invention provides a new application of the composition of Swertia eight flavors, specifically relates to the application of the composition of Swertia eight flavors in the preparation of medicines for treating atrophic gastritis, and belongs to the technical field of medicine. Background technique [0002] Bawei Swertia Pill is a classic Tibetan medicine, approved by the state, the executive standard number is WS3-BC-0241-95, and the prescription consists of Swertia, Rabbit Ear Grass, Boling Melon Seeds, Horned Fennel, Bangga, Berberis Eight medicinal materials such as skin, rock ginseng, woody incense, etc., the functions and indications are clearing away heat and reducing inflammation. It is used for cholecystitis and initial jaundice hepatitis, and its ingredients are safe and have no toxic and side effects. The eight-flavored Swertia composition currently has many different dosage forms, such as pills, powders, tablets, capsules and the like....
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.